Seth H. Z. Fischer
CIK 1573553 · Chief Executive Officer · last filed 2026-07-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SPPI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6310 NANCY RIDGE DRIVE, SUITE 101
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 0 | $3.18 | $0 | $0 | 7 | 2026-07-13 |
| MIST | Director | — | $0.65 | — | $0 | 5 | 2026-06-12 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Director | 0 | $0.55 | $0 | -$6.7K | 11 | 2025-02-11 |
| SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted | Director | 0 | $1.03 | $0 | -$55.4K | 6 | 2023-08-01 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | 976 | $1.51 | $1.5K | $0 | 8 | 2023-06-09 |
| Streamex Corp. (BSGM) Delisted | Director | 6,000 | $6.35 | $38.1K | $0 | 1 | 2018-11-09 |
| VIVUS INC (VVUS) Delisted | Chief Executive Officer | 63,398 | — | — | $18.7K | 9 | 2018-01-03 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | — | — | — | $0 | 2 | 2013-05-23 |
Recent Filings · Page 5 of 6
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-09-28 | VIVUS INC (VVUS) Delisted | Grant (A) | +300,000 | $0 | EDGAR |
| 2016-09-28 | VIVUS INC (VVUS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-28 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-26 | VIVUS INC (VVUS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-08-05 | VIVUS INC (VVUS) Delisted | Grant (A) | +117,000 | $0 | EDGAR |
| 2015-01-27 | VIVUS INC (VVUS) Delisted | Grant (A) | +66,000 | $0 | EDGAR |
| 2014-03-12 | VIVUS INC (VVUS) Delisted | Buy (P) | +3,080 | $18.7K | EDGAR |
| 2013-09-13 | — | Disp (D) | — | $0 | |
| 2013-09-05 | VIVUS INC (VVUS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-23 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.